ERBB2 and breast carcinoma: MCF7/HER2 and BT-474 breast cancer cell lines overexpressed the oncogenic receptor tyrosine kinase, HER2/ErbB2, which activates NF-κB and diminishes the responsiveness to tamoxifen [103].